Recipharm to formulate, fill and finish Moderna’s vaccine candidate

The partners in Pandemic Antiviral Discovery (PAD) initiative has announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans. These grants mark the majority of the first investments to come from the PAD initiative, a global philanthropic collaboration […]

AstraZeneca’s COVID-19 vaccine, Vaxzevria, has been granted full Marketing Authorisation (MA) in the European Union (EU). Vaxzevria was originally granted a conditional Marketing Authorisation (cMA) due to the urgency of the COVID-19 pandemic. As there continues to be sufficient evidence of safety and efficacy confirming the benefits of Vaxzevria, the European Medicines Agency (EMA) has now granted a full […]

Evusheld, a long-acting antibody combination, has been approved in the European Union (EU) for the treatment of adults and adolescents with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. “COVID-19 remains an ongoing health concern for millions of Europeans and around the world, especially for […]

Researchers at Karolinska Institutet are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans. “This is […]

Two ongoing research studies funded by NordForsk are providing new knowledge about COVID-19 related to pregnancy and mental health. The Nordic countries have similar welfare systems, access to high-quality health data, and publicly funded health services. Together with citizens’ trust in research, this all represents a particular strength in this context, describes NordForsk. Five collaborative […]

Bavarian Nordic has provided an update on the Phase 3 development of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The upcoming Phase 3 trial has been redesigned to include a licensed mRNA-based vaccine (Comirnaty) in the comparator arm of the study, to potentially support the primary objective of the study and demonstrate that the […]

New research from Karolinska Institutet shows that a booster shot of mRNA vaccine to individuals who have received two doses of inactivated vaccine offers the same level of protection against COVID-19 as three doses of mRNA vaccine. “Our results indicate that one booster shot of an mRNA vaccine, as a complement to the cheaper but […]